Literature DB >> 11577145

Prevalence of type III secretion genes in clinical and environmental isolates of Pseudomonas aeruginosa.

Heather Feltman1, Grant Schulert1, Salman Khan1, Manu Jain1, Lance Peterson1, Alan R Hauser1.   

Abstract

The type III secretion system of Pseudomonas aeruginosa transports four known effector proteins: ExoS, ExoT, ExoU and ExoY. However, the prevalence of the type III secretion system genes or the effector-encoding genes in clinical and environmental isolates of P. aeruginosa has not been well studied. Southern hybridization analyses and PCR were performed on over 100 P. aeruginosa isolates to determine the distribution of these genes. Clinical isolates were obtained from urine, endotracheal, blood and wound specimens, from the sputum of cystic fibrosis (CF) patients, and from non-hospital environmental sites. The popB gene was used as a marker for the presence of the large chromosomal locus encoding the type III secretion machinery proteins. Each isolate contained the popB gene, indicating that at least a portion of this large chromosomal locus was present in all isolates. Likewise, each isolate contained exoT-like sequences. In contrast, the exoS, exoU and exoY genes were variable traits. Overall, 72% of examined isolates contained the exoS gene, 28% contained the exoU gene, and 89% contained the exoY gene. Interestingly, an inverse correlation was noted between the presence of the exoS and exoU genes in that all isolates except two contained either exoS or exoU but not both. No significant difference in exoS, exoU or exoY prevalence was observed between clinical and environmental isolates or between isolates cultured from different disease sites except for CF respiratory isolates. CF isolates harboured the exoU gene less frequently and the exoS gene more frequently than did isolates from some of the other sites of infection, including the respiratory tract of patients without CF. These results suggest that the P. aeruginosa type III secretion system is present in nearly all clinical and environmental isolates but that individual isolates and populations of isolates from distinct disease sites differ in their effector genotypes. The ubiquity of type III secretion genes in clinical isolates is consistent with an important role for this system in human disease.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11577145     DOI: 10.1099/00221287-147-10-2659

Source DB:  PubMed          Journal:  Microbiology        ISSN: 1350-0872            Impact factor:   2.777


  165 in total

1.  Traversal of multilayered corneal epithelia by cytotoxic Pseudomonas aeruginosa requires the phospholipase domain of exoU.

Authors:  Julio C Ramirez; Suzanne M J Fleiszig; Aaron B Sullivan; Connie Tam; Roya Borazjani; David J Evans
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-01-25       Impact factor: 4.799

2.  Strain-dependent induction of neutrophil histamine production and cell death by Pseudomonas aeruginosa.

Authors:  Xiang Xu; Hong Zhang; Yuanlin Song; Susan V Lynch; Clifford A Lowell; Jeanine P Wiener-Kronish; George H Caughey
Journal:  J Leukoc Biol       Date:  2011-11-10       Impact factor: 4.962

3.  O-antigen serotypes and type III secretory toxins in clinical isolates of Pseudomonas aeruginosa.

Authors:  Karine Faure; David Shimabukuro; Temitayo Ajayi; Leonard R Allmond; Teiji Sawa; Jeanine P Wiener-Kronish
Journal:  J Clin Microbiol       Date:  2003-05       Impact factor: 5.948

4.  V-antigen genotype and phenotype analyses of clinical isolates of Pseudomonas aeruginosa.

Authors:  Leonard R Allmond; Temitayo Ajayi; Kiyoshi Moriyama; Jeanine P Wiener-Kronish; Teiji Sawa
Journal:  J Clin Microbiol       Date:  2004-08       Impact factor: 5.948

5.  Self-generated diversity produces "insurance effects" in biofilm communities.

Authors:  Blaise R Boles; Matthew Thoendel; Pradeep K Singh
Journal:  Proc Natl Acad Sci U S A       Date:  2004-11-16       Impact factor: 11.205

Review 6.  Contact lens-related microbial keratitis: how have epidemiology and genetics helped us with pathogenesis and prophylaxis.

Authors:  F Stapleton; N Carnt
Journal:  Eye (Lond)       Date:  2011-12-02       Impact factor: 3.775

7.  In vivo discrimination of type 3 secretion system-positive and -negative Pseudomonas aeruginosa via a caspase-1-dependent pathway.

Authors:  Tamding Wangdi; Lilia A Mijares; Barbara I Kazmierczak
Journal:  Infect Immun       Date:  2010-09-07       Impact factor: 3.441

8.  Role of the membrane localization domain of the Pseudomonas aeruginosa effector protein ExoU in cytotoxicity.

Authors:  Jeff L Veesenmeyer; Heather Howell; Andrei S Halavaty; Sebastian Ahrens; Wayne F Anderson; Alan R Hauser
Journal:  Infect Immun       Date:  2010-05-17       Impact factor: 3.441

9.  The ADP ribosyltransferase domain of Pseudomonas aeruginosa ExoT contributes to its biological activities.

Authors:  L Garrity-Ryan; S Shafikhani; P Balachandran; L Nguyen; J Oza; T Jakobsen; J Sargent; X Fang; S Cordwell; M A Matthay; J N Engel
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

10.  Pseudomonas aeruginosa uses T3SS to inhibit diabetic wound healing.

Authors:  Josef Goldufsky; Stephen J Wood; Vijayakumar Jayaraman; Omar Majdobeh; Lin Chen; Shanshan Qin; Chunxiang Zhang; Luisa A DiPietro; Sasha H Shafikhani
Journal:  Wound Repair Regen       Date:  2015-07-27       Impact factor: 3.617

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.